Chloride-substituted Ramalin derivatives differ from current AD treatments like cholinesterase inhibitors and NMDA receptor antagonists by targeting both tau aggregation and BACE-1 activity, potentially slowing or reversing disease progression. Here, BACE1 is linked to Alzheimer disease.